Suppression of the Shh pathway using a small molecule inhibitor eliminates medulloblastoma in Ptc1+/−p53−/− mice  by Romer, Justyna T. et al.
A R T I C L E
Suppression of the Shh pathway using a small molecule
inhibitor eliminates medulloblastoma in Ptc1/p53/ mice
Justyna T. Romer,1 Hiromichi Kimura,1 Susan Magdaleno,1 Ken Sasai,1 Christine Fuller,1 Helen Baines,1
Michele Connelly,1 Clinton F. Stewart,1 Stephen Gould,2 Lee L. Rubin,2 and Tom Curran1,*
1Department of Developmental Neurobiology, St. Jude Children’s Research Hospital, Memphis, Tennessee 38105
2 Curis, Inc., Cambridge, Massachusetts 02478
*Correspondence: tom.curran@stjude.org
Summary
Medulloblastoma is the most common malignant pediatric brain tumor. Current treatment is associated with major long-
term side effects; therefore, new nontoxic therapies, targeting specific molecular defects in this cancer, need to be
developed. We use a mouse model of medulloblastoma to show that inhibition of the Sonic Hedgehog (Shh) pathway
provides a novel therapy for medulloblastoma. A small molecule inhibitor of the Shh pathway, HhAntag, blocked the
function of Smoothened in mice with medulloblastoma. This resulted in suppression of several genes highly expressed in
medulloblastoma, inhibition of cell proliferation, increase in cell death and, at the highest dose, complete eradication of
tumors. Long-term treatment with HhAntag prolonged medulloblastoma-free survival. These findings support the develop-
ment of Shh antagonists for the treatment of medulloblastoma.
Introduction 2003). There is a critical need for new, nontoxic therapies for
medulloblastoma.
The first indication that alteration in the Shh pathway contrib-Research in molecular oncology has benefited from the advent
of mouse models of human cancer (Hesselager and Holland, utes to medulloblastoma formation was the discovery that germ-
line mutations in the Shh receptor, Patched-1 (PTCH1), underlie2003; Van Dyke and Jacks, 2002). Genetically engineered mouse
strains have been used to investigate tumor etiology and to the human developmental disorder Gorlin syndrome (Gorlin,
1995; Hahn et al., 1996; Johnson et al., 1996). Gorlin syndrome,elaborate the molecular pathways that contribute to human can-
cer. However, the greatest potential application of such models also known as Basal Cell Nevus Syndrome, is characterized
by large body size, developmental and skeletal abnormalities,is to pioneer the development of novel therapies that are spe-
cifically targeted against growth control pathways altered in fibromas of soft tissue, radiation sensitivity, basal cell carci-
noma, and increased incidence of medulloblastoma (Goodrichcancer. For this purpose, it is necessary that mouse models
recapitulate both the genetics and the biology of the corre- and Scott, 1998; Kimonis et al., 1997). Heterozygous loss of
PTCH1 occurs in approximately 10% of sporadic human medul-sponding human disease. It is also critical that the tumor inci-
dence is high and the age of onset is predictable, to ensure loblastoma (Ellison et al., 2003; Wechsler-Reya and Scott, 2001),
and mutations in downstream components of the Shh pathway,that cohorts of mice bearing tumors can be identified and treated
with potential anticancer drugs. Previously, we developed a high Smoothened (SMOH) and Suppressor of Fused (SUFU), which
lead to activation of the pathway, have also been describedincidence mouse model for the pediatric brain tumor medul-
loblastoma (Wetmore et al., 2001). Medulloblastoma, a primitive (Reifenberger et al., 1998; Taylor et al., 2002). In mice, heterozy-
gous mutation of Patched-1 (Ptc1) is associated with an approxi-neuroectodermal tumor, arises in the cerebellum and accounts
for approximately 20% of all pediatric brain tumors. Current mately 20% incidence of medulloblastoma over a period of
1 year (Corcoran and Scott, 2001; Goodrich et al., 1997; Wet-treatment involves surgical resection, chemotherapy, and radia-
tion of the craniospinal axis (Ellison et al., 2003). Although the more et al., 2000). We accelerated the incidence and decreased
the latency of medulloblastoma by crossing Ptc1/ mice withoverall 5 year survival rate is approximately 70%, treatment is
associated with long-term side effects including ataxia, neuro- p53/mice (Wetmore et al., 2001). Ptc1/p53/mice develop
medulloblastoma and most die from brain tumors within 12endocrine problems, intellectual deterioration, and neuropsy-
chological difficulties (Chintagumpala et al., 2001; Ellison et al., weeks of birth. P53 is mutated in approximately 10% of human
S I G N I F I C A N C E
Therapy for pediatric cancers of the CNS has not improved significantly in the last three decades. This is partly due to the absence
of adequate model systems for testing novel therapies. Current models are based on xenografts, allografts, or in vitro culture of
human tumor cells. In these models, the cancer cells are removed from their normal environment, undergo selective pressure, and
may not be representative of the original tumor. Cancer models should recapitulate the causative genetic lesions and the anatomical
location and developmental time frame of the corresponding human disease. Here, we use such a model to test a novel therapy
for medulloblastoma; we show that suppression of the Sonic Hedgehog pathway can be an effective treatment for this tumor.
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Figure 1. The Shh pathway is downregulated in cultured medulloblastoma cells
A: HhAntag and cyclopamine inhibit growth of cultured NIH3T3 and medulloblastoma cells at similar concentrations. The graph shows the percentile
change in cell growth, as determined by Alamar blue staining, following treatment of cells with increasing concentrations of HhAntag or cyclopamine.
The medulloblastoma cell cultures, SJMM1 and SJMM2, were derived from Ptc1/ tumors, whereas SJMM7 and SJMM12 were derived from Ptc1/p53/
tumors.
B: The Shh pathway was activated in NIH3T3 cells containing a Gli-luciferase reporter by treatment with 100 ng/ml ShhN, and the inhibitory effects of
HhAntag and cyclopamine were compared. HhAntag is 10 times better than cyclopamine at inhibiting Shh activity. Note that the concentration of
HhAntag required to inhibit cell growth is approximately 1000-fold higher than that needed to suppress Shh activity.
C: Shh induces Gli-luciferase activity in NIH3T3 cells but not in medulloblastoma cell cultures. Medulloblastoma cultures and NIH3T3 cells transfected with
a Gli-luciferase reporter plasmid were treated with increasing doses of Shh.
D: Gli1 is highly expressed in medulloblastoma in vivo but is downregulated in cell lines derived from tumors. Total RNA, isolated from normal cerebella,
medulloblastoma, or medulloblastoma cultures, was analyzed by hybridization to a Gli1 probe. Ethidium bromide staining of the 28S and 18S rRNA is shown
as a loading control.
E: Gli1 can activate target genes in medulloblastoma cells. Cells were infected with a retroviral vector expressing an HA-tagged full-length Gli1 cDNA.
RNA was isolated and analyzed by hybridization to probes specific for Gli1, Ptc1, Ptc2, and Smo. Ethidium bromide staining of the 28S and 18S rRNA is
shown as a loading control.
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medulloblastoma, and the P53 pathway is defective in a larger Results
subset of tumors (Ellison, 2002; Frank et al., 2004; Kleihues et
HhAntag blocks Shh signaling at concentrationsal., 1997). In addition, germline mutations of P53 are associated
that do not affect cell growthwith medulloblastoma in Li-Fraumeni syndrome (Malkin et al.,
As a first step in analyzing the ability of HhAntag to block medul-1990). Thus, Ptc1/p53/ mice provide a useful model to
loblastoma growth, we treated cultured tumor cells derived fromdevelop novel therapies for brain tumors, targeted against the
Ptc1/ and Ptc1/p53/ mice as well as NIH3T3 cells withShh pathway.
increasing concentrations of HhAntag or cyclopamine. We mea-During brain development, Shh released by migrating Pur-
sured the effects on cell growth, as determined by Alamar bluekinje cells binds to Ptc1 present on granule neuron precursor
staining, and found that both compounds exhibited similar IC50(GNP) cells in the external germinal layer (EGL) of the cerebellum
values in growth assays (10–30M), with growth of some medul-(Wechsler-Reya and Scott, 2001). This interaction causes dere-
loblastoma cultures inhibited more readily by cyclopamine thanpression of Smoothened (Smo) (Taipale et al., 2002) and in-
HhAntag (Figure 1A). Similar results were obtained when wecreased expression of transcription factor Gli1 and proliferation
used cell counts as a measure of proliferation. Next, we lookedof GNP cells. The Shh pathway is critical during embryogenesis
at the concentration of HhAntag and cyclopamine required to
but is downregulated after early postnatal development in most
suppress the Shh pathway. We transfected NIH3T3 cells with
tissues, including the brain. In contrast, more than 30% of hu- a Gli-luciferase reporter construct and measured inhibition of
man medulloblastoma exhibit high levels of GLI1 expression the Shh pathway by the two compounds following maximal
(Lee et al., 2003), indicating that abnormal activation of the Shh stimulation by Shh (Figure 1B). HhAntag was significantly more
pathway is important in a subset of pediatric brain tumors. Thus, potent than cyclopamine at suppressing Shh signaling; it exhib-
the Shh pathway is a potential therapeutic target for develop- ited an EC50 of 0.04 M compared to 0.5 M for cyclopamine
ment of novel treatments for medulloblastoma. (Figure 1B). Surprisingly, the drug concentrations required to
Cyclopamine, an alkaloid isolated from the corn lily Veratrum block cell growth were higher than those required to inhibit Smo
californicum (Binns et al., 1963; Keeler and Binns, 1968), has activity by approximately 100- and 1000-fold for cyclopamine
been shown to suppress the response of target tissues to Shh and HhAntag, respectively. Indeed, both HhAntag and cyclo-
(Cooper et al., 1998) by binding to Smo (Chen et al., 2002). pamine were able to completely suppress Shh activation of Gli-
Recent observations suggest that cyclopamine inhibits the luciferase in NIH3T3 cells at concentrations that did not affect
growth of cultured medulloblastoma cells and allografts by in- cell growth. These results support the selection of HhAntag as a
hibiting Smo (Berman et al., 2002). However, cyclopamine is potent Smo inhibitor for preclinical studies on medulloblastoma.
However, they also raise the concern that growth inhibition innot a good drug candidate for treatment of medulloblastoma
cell culture may not be related to inhibition of Smo, as thebecause it has a relatively low affinity for Smo. High-throughput,
concentrations that suppressed the Shh pathway were 100- tocell-based screening assays identified several small molecule
1000-fold lower than those that inhibited cell growth.inhibitors of the Shh pathway (Williams et al., 2003). One of
these compounds, a benzimidazole derivative, Hh-Antag691,
The Shh pathway is not active in culturedhere referred to as HhAntag (Gabay et al., 2003), exhibited higher
medulloblastoma cellsaffinity for Smo than cyclopamine, blocking Shh function at10-
To investigate the status of the Shh pathway in cultured medul-fold lower concentrations. HhAntag penetrates the blood-brain
loblastoma cells, we treated NIH3T3 cells and medulloblastomabarrier after oral delivery, making it an ideal candidate for treat-
cultures containing a Gli-luciferase construct with Shh (Figurement of brain tumors caused by increased activity of Smo.
1C). Although NIH3T3 cells exhibited a strong dose-dependentTherefore, we selected HhAntag to treat medulloblastoma in
increase in luciferase activity in response to Shh, all of thePtc1/p53/ mice. We found that HhAntag inhibited Gli1 ex-
medulloblastoma cultures failed to respond. Previously, we re-
pression in a dose-dependent manner in tumor tissue in vivo.
ported that medulloblastomas express high levels of Gli1, indi-
Treatment of tumor-bearing mice twice daily with HhAntag at cating that the Shh pathway is active in tumors in vivo (Wetmore
20 or 100 mg/kg of body weight, by oral gavage, for 4 days, et al., 2001). However, examination of mRNA levels in cultured
inhibited tumor cell proliferation and increased apoptosis. Twice medulloblastoma cells revealed that Gli1 mRNA was much re-
daily treatment of mice for 2 weeks with 20 mg/kg of HhAntag duced or absent in vitro (Figure 1D). To ensure that the down-
resulted in reduction of tumor volume, and complete elimination stream components of the Shh pathway were intact in medul-
of tumors was observed in mice treated with 100 mg/kg HhAn- loblastoma cell cultures, we confirmed the presence of normal
tag. In longer-term studies, 100 mg/kg HhAntag given once Smo and Ptc1 mRNA by sequencing cDNA derived from tumor
a day significantly enhanced brain tumor-free survival. These cell RNA. In addition, we demonstrated that ectopic expression
results suggest that HhAntag may be beneficial for treatment of Gli1, using a retroviral vector, increased expression of the
of medulloblastoma and other tumors in which the Shh pathway endogenous target genes Gli1, Ptc1, and Ptc2 (Figure 1E). These
findings demonstrate that the Shh pathway is suppressed inis deregulated.
F: HhAntag efficiently blocks Shh-induced proliferation of GNP cells in a dose-dependent manner. GNP cells, isolated from postnatal day 6 mice, were
treated with 100 ng/ml ShhN in the presence of increasing concentrations of HhAntag. Cell proliferation was measured by determining the fold difference
in BrdU incorporation, relative to incorporation in the absence of Shh. Note, much lower concentrations of HhAntag block growth of GNP cells than those
required to block growth of medulloblastoma cells in culture.
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cultured medulloblastoma cells at a step between Smo and Gli1 comparable to that in normal developing cerebellum (Wetmore
and they imply that growth inhibition caused by exposure to et al., 2000). This agrees with the original report from Goodrich
cyclopamine and HhAntag in vitro (Figure 1A) is not mediated et al. (1997) demonstrating expression of the mutated Ptc1 allele
by inactivation of Smo. In contrast to the high concentration of in tumor cell by -gal staining. Thus, although Ptc1 expression
drug required to inhibit growth of medulloblastoma and NIH3T3 has been used to monitor the response of mouse medulloblas-
cells, HhAntag efficiently blocked Shh-mediated proliferation of toma cells to Smo inhibition in vitro (Berman et al., 2002), it
GNP cells at the same low concentrations that inhibited Gli- appears that Ptc1 is not a target of the Shh pathway in these
luciferase activity (Figure 1F). Thus, it is possible that additional tumor cells in vivo.
factors present in the intracranial environment and absent in The reduction in mRNA levels of Shh pathway target genes
culture are needed to maintain the ability of medulloblastoma observed in the short-term study was not simply due to loss of
cells to respond to Shh. tumor mass following treatment with HhAntag, as histological
analyses of cerebella from treated mice indicated that tumors
HhAntag inhibits the Shh pathway in medulloblastoma were present in all treated mice. To confirm that gene expression
cells in vivo was decreased in tumor cells in vivo, we conducted in situ
The results presented above indicate that Smo activity is not hybridization analyses of brain sections using probes specific
required for proliferation of medulloblastoma cells in culture. To for Gli1, Sfrp1, Math1, Ptc1, Ptc2, and Reln genes (Figure 3).
determine if Smo activity can be blocked in tumor cells in vivo, Consistent with the quantitative PCR analysis, we found that
we analyzed Gli1 expression in Ptc1/p53/ mice treated with Gli1, Sfrp1, Math1, and Ptc2 were expressed mostly in the tumor
HhAntag. Cohorts of mutant mice were treated with HhAntag, cells and not in the adjacent normal cerebellum. There was a
administered twice daily by oral gavage, for 4 days, at 20 or marked decrease in expression of all of these genes in response
100 mg/kg of body weight. To control for nonspecific effects, to 20 mg/kg of HhAntag and a complete absence of expression
we also treated a cohort of mutant mice with vehicle. Treatment following treatment with 100 mg/kg, despite the presence of
was initiated in 6-week-old Ptc1/p53/ mice, as they contain substantial tumor mass (Figure 3). When the decrease in gene
substantial tumor mass at this age. At the end of the dosing expression levels between vehicle and 100 mg/kg HhAntag-
regimen, mice were euthanized and total RNA was isolated from treated mice (7- to 300-fold changes, depending on the gene)
tumor tissue together with the entire cerebellum. This approach is compared with the decrease observed in tumor cell density
reduces sampling errors that would be introduced by attempting (1.8-fold), it is clear that the loss of gene expression is not
to dissect tumor tissue free from normal cerebellum. Tumors in
simply due to the reduction in cell number following treatment.
Ptc/p53/ mice arise in very young mice, and they are inti-
In agreement with the real-time PCR data, wild-type Ptc1 mRNA
mately associated with normal cerebellar structure. By combin-
was present at relatively low levels in the tumor tissue, and its
ing tumor tissue and the complete cerebellum, we ensure that
expression did not change after drug treatment (Figure 3). Thethe normal component of each sample is constant and the
control gene, Reln, was still expressed at high levels in tumordifferences observed in gene expression reflect changes in tu-
present in the drug-treated mice. Thus, HhAntag selectivelymor cells. We also measured the level of HhAntag in the re-
suppressed Shh pathway target genes in vivo by blocking Smomaining brain tissue to confirm that the compound penetrated
signaling in medulloblastoma cells, with complete suppressionthe blood-brain barrier. The mice treated with 20 and 100 mg/
at 100 mg/kg given twice a day.kg of HhAntag contained an average of 0.38 and 2.0 mg/kg of
drug, respectively, and no compound was detected in vehicle-
HhAntag affects morphology and growthtreated mice (Figure 2A).
of Ptc1/p53/ medulloblastomaQuantitative real-time PCR analysis of Gli1 expression levels
Since HhAntag effectively blocked Smo activity in mice treatedrevealed extensive variation among control samples (Figure 2A).
for 4 days, we analyzed the morphology of treated tumors.This was expected, as the time of tumor development and tumor
Neuropathological examination readily distinguished among tu-growth rate vary among individual mice in this spontaneous
mors from untreated and 20 or 100 mg/kg of HhAntag-treatedbrain tumor model. Therefore, we used the Exact Kruskal-Wallis
mice (Figure 4A). Although all tumors were composed of smalltest to determine whether the results reflected significant differ-
round cells with oval to carrot-shaped hyperchromatic nucleiences in gene expression among the different treatment groups
and minimal surrounding cytoplasm, those in the treated mice(Figure 2B). HhAntag effectively suppressed Gli1 mRNA levels
less often formed large, confluent tumor masses. The lesionsin a dose-dependent manner in vivo (Figures 2A and 2B). In
in treated mice more often manifest as small collections ofaddition to Gli1, we examined the levels of several other genes
individual tumor cells in the superficial confines of the cerebellar(Sfrp1, Math1, and Ptc2) previously identified to be highly ex-
molecular layer. The most striking difference observed amongpressed in Ptc1/p53/ medulloblastoma (Lee et al., 2003).
the three groups was a dramatic decrease in mitotic activityWe found a dose-dependent decrease in mRNA levels of these
(Figure 4B). Immunohistochemical staining with the Ki67 markergenes in response to HhAntag (Figure 2B). As a control, we
for cell proliferation confirmed the observation that HhAntagexamined expression of Reln, which is present in GNP and
decreased the proliferative index in tumor tissues (p  0.0001,tumor cells (Wetmore et al., 2000) but is not known to be under
Exact Kruskall-Wallis) (Figure 4C). We also observed more cellcontrol of the Shh pathway. The Reln levels were not affected
death in tumors from treated mice, as indicated by increasedby drug treatment (Figure 2B). Surprisingly, transcription of the
numbers of pyknotic nuclei (Figure 4B) and by TUNEL assaywild-type allele of Ptc1, which like Gli1 is a target of Shh signal-
(p  0.0402, Exact Kruskall-Wallis) (Figure 4C). The influx ofing, was unaffected by drug treatment (Figure 2B). Previously,
macrophages and microglia into the drug-treated tumors (aswe demonstrated that both the normal and the mutated Ptc1
alleles are expressed in Ptc1/ medulloblastoma cells at levels determined by Mac2 immunohistochemistry) increased from
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Figure 2. HhAntag suppresses the Shh pathway
in mouse medulloblastoma in vivo
A: Real-time PCR analyses of total RNA isolated
from tumor-bearing cerebella showing Gli1 ex-
pression in mice treated twice daily for 4 days
with HhAntag at 20 or 100 mg/kg or with vehicle
alone. The amount of HhAntag present in each
treated brain, 4 hr after the last dose, is indicated
under each of the bars.
B: Box plots derived using Exact Kruskal-Wallis test
to analyze gene expression in the treated brains
showing that HhAntag suppressed Gli1, Sfrp1,
Math1, and Ptc2, but not Ptc1. Reln, a gene ex-
pressed in medulloblastoma, but not under con-
trol of the Shh pathway, was analyzed as a con-
trol. Levels of mRNA for all assayed genes were
within the linear range of a standard curve de-
rived by amplifying each gene from serially di-
luted RNA, isolated from an independent source.
2.5% of Mac2-positive cells in vehicle-treated tumors to 5% cle group, four out of five mice exhibited an overwhelming tumor
burden and only one mouse had a small tumor. In contrast, inand 7% in tumors treated with 20 and 100 mg/kg of HhAntag,
respectively. Macrophage infiltration is associated with damage the cohort treated with 20 mg/kg of HhAntag, one mouse had
a very large tumor, three had small tumors, and one had almostor loss of cells and it is not necessarily indicative of necrosis.
In fact, necrosis was not observed in any of the tumors treated no tumor, whereas in the 100 mg/kg treatment group, one
mouse had a large tumor, one had a medium-sized tumor, andwith HhAntag. HhAntag treatment also caused a dose-depen-
dent increase in expression of the astrocyte marker, GFAP, three mice showed almost no tumor burden. Representative
sagittal sections, taken through the largest tumor cross-section,which is characteristic of reactive gliosis often associated with
CNS trauma. Taken together, the data presented above indicate are shown in Supplemental Figure S1. Although the short-term
treatment with HhAntag appeared to inhibit tumor growth, thethat even a short-term treatment with HhAntag inhibited tumor
growth. differences in tumor size between vehicle- and drug-treated
mice were not dramatic. Therefore, we designed a study toAfter completion of treatment, we observed that, in the vehi-
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determine the effect of HhAntag on tumor volume in Ptc1/
p53/ mice treated for the extended period of 2 weeks.
HhAntag eliminates tumor mass in Ptc1/p53/ mice
To determine the effects of HhAntag on tumor growth, mice
were treated for 14 days, twice daily, at either 20 or 100 mg/
kg, or with vehicle alone. Treatment was initiated when mice
were 3 weeks old, at which age all Ptc1/p53/ mice exhibit
discernible tumor mass but not of a size that could adversely
affect their health and short-term survival. At the end of the
treatment period, brains were prepared for histological examina-
tion. We found that all the vehicle-treated mice had substantial
tumor mass, whereas mice treated with 20 mg/kg of HhAntag
had much smaller tumors and no tumor mass could be detected
in the 100 mg/kg treatment group (Figure 5A). We used three-
dimensional reconstruction analysis to measure tumor volumes
by tracing sections at 150 m intervals through the cerebellum
(Figures 5B and 5C). Both the remaining normal IGL and the
tumor areas were traced, and the tracings were aligned using
the IGL as a guide to reconstruct tumor volume in 3D (Figures
5D and 5E). This is illustrated as a 3D computer-generated
image with the IGL in blue (Figure 5D) and the tumor volume in
several colors (Figures 5D and 5E). The IGL volume was sub-
tracted in Figure 5E to clearly identify the total tumor volume
in this example. Quantitative analysis revealed a marked de-
crease of tumor size in mice treated with 20 mg/kg HhAntag and
a complete elimination of measurable tumor volume following
treatment with 100 mg/kg HhAntag (Figure 5F). There was varia-
tion in the tumor mass present in the untreated cohort
(5.6–34.8 mm3) and in the 20 mg/kg treated mice (0.11–7.56
mm3). The range of volumes was greater in untreated mice, as
indicated by the standard deviation of 12.8 compared to 2.9
for the 20 mg/kg treated mice. The overall reduction in tumor
volumes following treatment with HhAntag was examined using
the Exact Kruskall-Wallis test; the Monte Carlo estimate of the
p value (0.0001) suggests a highly statistically significant dif-
ferences in tumor volume distribution among the three treatment
groups. We also found that there was a dose-dependent effect
of HhAntag on tumor volume as indicated by the Exact Wil-
coxon-Mann-Whitney test (p  0.0159). There was an approxi-
mate 7-fold reduction in tumor volume between the untreated
mice and mice treated with 20 mg/kg HhAntag (from an average
of 19 mm3 to 2.5 mm3). Strikingly, complete tumor regression
was observed following treatment of mice with 100 mg/kg
HhAntag. In two of the four mice treated, no tumor remained
at all. However, we did observe small lesions, indicating evi-Figure 3. Treatment of Ptc1/p53/ mice with HhAntag suppresses Gli1,
dence of regression in the most lateral aspect of the cerebellumSfrp1, Math1, and Ptc2, but not Ptc1 in medulloblastoma
of the other two mice (Figure 5G). These areas showed noIn situ hybridization analyses were performed using radiolabeled probes on
brain tissue from Ptc1/p53/ mice. Expression of Gli1, Sfrp1 Math1, and evidence of proliferation and they contained scattered apoptotic
Ptc2 genes was downregulated after 4 days of treatment, twice daily with bodies and focal reactive changes, particularly lymphocyte infil-
20 mg/kg of HhAntag, and completely suppressed following treatment with trate from leptomeningeal blood vessels. The lesions were con-100 mg/kg HhAntag. Ptc1 mRNA was present at low levels in the tumor and
fined to the molecular layer and the subpial zone. Thus, HhAn-in the normal Purkinje cell and internal granule cell layers. Treatment with
HhAntag did not alter the pattern or intensity of the Ptc1 signal. Reln mRNA, tag, given twice daily at 100 mg/kg, effectively eliminated
highly expressed in medulloblastoma, did not change following treatment. medulloblastoma in Ptc1/p53/ mice.
The panels on the far right show adjacent paraffin sections of the tumor-
bearing cerebella, stained with haematoxylin and eosin, tumor regions out-
HhAntag prolongs brain tumor-free survivallined. Scale bar equals 800 m.
of Ptc1/p53/ mice
To determine if HhAntag could prolong survival of Ptc1/p53/
mice, we treated 20 5-week-old mice with either 100 mg/kg of
the drug or vehicle, once daily for an extended period. The dose
was lower than used in the previous studies because of limited
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Figure 4. HhAntag inhibits proliferation, increases
apoptosis, and alters morphology of medullo-
blastoma cells in vivo
A: Sections of brain tissue from mice treated
twice daily with vehicle or HhAntag at 20 or 100
mg/kg, at low magnification. Scale bar equals
500 m.
B: High magnification of A. Scale bar equals
50 m. The locations of the regions examined
at high magnification are indicated by black
boxes. Note the increase in apoptotic bodies
(black arrowheads) and the decrease in mito-
tic figures (white arrowheads) associated with
HhAntag treatment. All sections were stained
with haematoxylin and eosin.
C: Quantitative analyses of proliferation and
apoptosis in tumors are presented as box plots.
The data were obtained by counting Ki67- (prolif-
eration) and TUNEL- (apoptosis) positive cells in
the drug- and vehicle-treated mice. The data
were analyzed using the Exact Kruskall-Wallis
tests, with Monte Carlo estimates of p values
of 0.0001 for proliferation and 0.0402 for apo-
ptosis, suggesting statistically significant differ-
ence among the three treatment groups.
availability of the HhAntag compound and the concern that five mice in the treated cohort were euthanized after exhibiting
symptoms of other tumors typical of p53 null mice, includingprolonged, twice daily delivery of the drug by oral gavage could
result in injury. Also due to the limited availability of HhAntag, thymic lymphomas, soft tissue sarcomas, and teratomas. How-
ever, each of these mice also showed evidence of small medullo-four of the ten mice receiving HhAntag were removed from drug
after 50 days of treatment. All mice treated with vehicle alone blastomas when the brain was removed and examined. These
results indicate that treatment of mice with 100 mg/kg of HhAn-developed clinical signs of brain tumors, such as domed head,
ataxia, and tilting of the body, and were euthanized between 4 tag once daily did not completely eliminate medulloblastoma.
This is most probably because the dose of drug used, whileand 74 days after the start of treatment. In contrast, drug-treated
mice survived significantly longer (39 to 147 days), and only five sufficient to retard tumor growth, was not high enough to cause
total regression. Nevertheless, analyses of the data revealedmice were euthanized due to brain tumors (Figure 6). Three of
these had received HhAntag for only 50 days. The remaining that HhAntag significantly extended the period of brain tumor-
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Figure 5. HhAntag given twice daily eliminates
tumor mass in vivo
A: Sections of brain tissue from a wild-type mouse
(normal cerebellum) and Ptc1/p53/ mice
treated twice daily with vehicle or HhAntag at
20 or 100 mg/kg are shown. Treatment was initi-
ated at three weeks of age. Scale bar equals
500 m.
B–E: Determination of tumor volumes using the
Bioquant Nova 3D reconstruction program.
B: An example of a 5 m sagittal section from
an untreated Ptc1/p53/ mouse, stained with
cresyl violet. Scale bar equals 500 m.
C: The outline of the IGL is indicated by the blue
trace, and the regions of tumor are traced in the
other colors. The different colors used for tracing
the tumor area mark separate regions of tumor.
D and E: Sections were traced every 150 m and
assembled to create 3D images of the tumor
(D) plus the IGL or the tumor alone (E). R, rostral
direction.
F: Tumor volumes from vehicle-treated mice and
from mice treated with HhAntag at 20 or 100
mg/kg are represented in a box plot. The Exact
Kruskall-Wallis test suggests a clear statistical dif-
ference in the distribution of tumor volumes
among the three groups (p  0.0001), and the
Exact Wilcoxon-Mann-Whitney test revealed sta-
tistically significant dose-dependent decrease in
tumor volume associated with HhAntag treat-
ment (p  0.0159).
G: Signs of tumor regression are present in some mice treated with 100 mg/kg of HhAntag, twice daily for 14 days. The figure shows a low-power image
in the left panel and a high-power view in the right panel of a lesion area (boxed in the low-power image). Infiltrating lymphocytes are indicated by a
black arrow. Scale bar equals 500 m for the low-power and 100 m for the high-power image. All sections were stained with haematoxylin and eosin
unless indicated otherwise.
free survival in Ptc1/p53/ mice (the Exact Two-Sided p pression in tumor cells and reduced tumor cell proliferation
value for Log-Rank Test was 0.0001). in vivo. At the highest dose used, there was no measurable
tumor volume after 2 weeks of treatment. Remarkably, although
Discussion tumor growth disrupts the structure of the cerebellum, cerebellar
morphology was relatively normal in the treated mice. These
In this study, an inhibitor of the Shh pathway, HhAntag, elimi- findings provide strong encouragement for the development of
nated tumor in a mouse model of spontaneous medulloblas- small molecules that block Smo function to treat tumors in which
toma. HhAntag blocked the ability of Smo to increase Gli1 ex- the Shh pathway is activated. Our findings extend previous
studies using cultured tumor cells and transplantable tumors in
which cyclopamine was shown to inhibit growth of mouse and
human tumor cells (Berman et al., 2002, 2003; Taipale et al.,
2000; Thayer et al., 2003). However, we also demonstrate that
the Shh pathway is downregulated in cultured mouse medul-
loblastoma cells and that inhibition of cell proliferation in culture
using cyclopamine and HhAntag is not mediated by inhibition
of Smo. In contrast, treatment of mice with HhAntag blocked
tumor growth at the same concentration that inhibited Smo
activity, as determined by the level of Gli1 expression. This
finding suggests that additional factor(s), present in the intra-Figure 6. Treatment of Ptc1/p53/ mice with HhAntag increases life ex-
pectancy cranial environment but missing in cell culture, are required to
maintain the ability of tumor cells to respond to Shh. TheseAt 5 weeks of age, mice were arbitrarily assigned into two groups of ten.
One cohort was treated once daily with 100 mg/kg of HhAntag, and the results underscore the utility of genetically programmed mouse
other with vehicle alone. The graph shows the cumulative incidence of tumor models in which effects of targeted therapies can be
euthanasia due to brain tumors in the presence of competing event: eutha-
determined in an appropriate in vivo context.nasia due to other tumors. The Exact two-sided p value for the log-rank test
HhAntag penetrated the blood-brain barrier after oral deliv-was 0.0001, indicating a highly significant difference in brain tumor-free
survival between HhAntag- and vehicle-treated mice. Due to the limited ery and efficiently suppressed tumor cell proliferation. Although
amount of drug available, after 50 days of treatment, drug was withheld apoptosis was increased in treated tumors, particularly at the
from four of the eight mice still alive in the treatment group. Three of these
highest dose used, this effect was modest. It is likely that themice subsequently developed medulloblastoma (the times of euthanasia
are indicated by arrows). major mechanism of action of HhAntag is antiproliferative; how-
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ever, we cannot rule out the possibility that a peak of cell death Additionally, complete sequencing of the normal Ptc1 allele,
using cDNA from tumors and tumor cell lines, demonstratedoccurs at an earlier time point during the treatment regime. The
basal apoptotic rate in tumors is quite high, so inhibition of that the remaining Ptc1 allele is not mutated. Therefore, haploin-
sufficiency of Ptc1 promotes medulloblastoma formation inproliferation would result in loss of tumor volume by attrition.
The loss of tumor volume was associated with macrophage Ptc1/ and Ptc1/p53/ mice. In tumor cells, Ptc1 is not
subject to the usual positive feedback regulation, as Ptc1 levels,infiltration and reactive gliosis but not necrosis. Future studies
will address the temporal mechanism of action of HhAntag. unlike those of Gli1, are not downregulated following suppres-
sion of the Shh pathway by the Smo inhibitor HhAntag in vivo.During the course of our experiments, we did not detect any
toxic side effects of the therapy. Even in prolonged studies, in This implies that there may be a defect in the autoregulatory
loop of the Shh pathway in tumor cells in vivo.which mice received 100 mg/kg of HhAntag every day for more
than 50 days, there were no signs of deleterious effects or The three-stage preclinical approach we devised to explore
the effect of a small molecule inhibitor in our mouse model mayweight loss in the treated group.
Treatment of mice with HhAntag for 2 weeks at 100 mg/kg have general application. In the first stage, we carried out a
short-term study demonstrating that HhAntag inhibited its tar-twice daily resulted in an absence of measurable tumor volume,
suggesting that at this dose, the tumor was eradicated before get, Smo, in tumor cells in vivo in a dose-dependent manner.
The second stage involved longer-term exposure of mice todrug resistance could develop. The high dose was crucial for
the tumor response, as there was only a partial regression in the compound followed by quantitative evaluation of the dose-
dependent effects of HhAntag on tumor growth. The final stage,the cohort of mice receiving 20 mg/kg. Furthermore, in the
survival study, in which HhAntag was given at 100 mg/kg once similar to human clinical trials, demonstrated that prolonged
exposure improved the survival of mice with tumors. At eacha day, mice still succumbed to medulloblastoma, albeit with a
significant delay compared to vehicle-treated mice. Thus, in stage, the drug was delivered by oral gavage to mimic the
potential dosing route in patients. To apply this approach, it isconsidering the use of HhAntag for treating human disease, it
will be important to use the appropriate dose to ensure complete critical to develop a high-incidence, early-onset mouse model,
consistent with the genetics of human tumors. It is likely thatsuppression of Smo in tumor cells. Alternatively, it may be possi-
ble to identify additional inhibitors that display more favorable such models represent only one particular molecular subtype of
the tumor, rather than the entire spectrum of the correspondingpharmacokinetics.
Although Gli1 is a target of Smo signaling, it is not yet known human disease. In our case, the activated Shh pathway in tumor
cells allowed testing of the proof of principle that inhibition ofif Gli1 mediates the oncogenic activity of the Shh pathway.
Recently, it was reported that a virus expressing Shh is capable Smo by a targeted therapy would block tumor growth in vivo.
For this strategy to be successful, it is important to identify aof inducing medulloblastoma in mice lacking Gli1 (Weiner et al.,
2002). Since Gli2 is functionally similar to Gli1, there may be reliable marker of pathway activity (Gli1 expression level in our
case) and to use compounds with good bioavailability in theredundancy and/or compensation among family members (Bai
et al., 2002; Park et al., 2000). However, in addition to suppres- target tissue. If these conditions can be met, the three-stage
approach described here can provide information on dose-sion of Gli1, we found that HhAntag also inhibited expression
of several other genes in tumor cells in vivo, including Gli2 dependent activity, tumor pathology, potential side effects, and
long-term survival.(data not shown). It is possible that some or all of these genes
contribute directly to oncogenesis. At present, it is not possible Since HhAntag works by suppressing Smo activity, it should
be effective against medulloblastomas in which upstream com-to distinguish between cause and effect: the changes in gene
expression could be responsible for the effect on tumor growth, ponents of the Shh pathway have been activated by mutation.
However, HhAntag may also have a broader application. Severalor the inhibition of tumor growth might have resulted in the
changes in gene expression. We are now pursuing time course mouse medulloblastoma models have been described in which
p53, together with PARP-1, Lig4, Rb, or different cell cycleexperiments and gene expression microarray studies to exam-
ine the differences in gene expression between treated and regulators have been mutated (Hesselager and Holland, 2003;
Lee et al., 2003). These tumors exhibit similar gene expressionuntreated mice. These studies will help to decipher the mode
of action of HhAntag. profiles to Ptc1/ medulloblastoma, including elevated Gli1 lev-
els, indicating that they may also be inhibited by HhAntag (LeeWe were surprised to discover that, in contrast to Gli1,
Math1, Ptc2, and Sfrp1, the level of Ptc1 was not reduced after et al., 2003). Approximately 25% of sporadic human medul-
loblastoma harbor mutations in different components of thetreatment with HhAntag. This was not expected, as Ptc1 is
induced in cell culture, including medulloblastoma cell cultures, Shh pathway (Ellison et al., 2003). These tumors are excellent
candidates for potential treatment with Smo inhibitors, and itby overexpression of Gli1. Previously, we reported that the wild-
type Ptc1 allele is expressed in medulloblastoma at a similar is also possible that some of the remaining 75% of human
medulloblastoma would respond to HhAntag. Inhibitors of thelevel to that observed in normal P7 and adult cerebellum (Wet-
more et al., 2000, 2001). These findings contrasted with a report Shh pathway may also be efficacious against other tumors with
an activated Shh pathway, such as most basal cell carcinomausing reverse-transcriptase PCR analysis to indicate that ex-
pression of Ptc1 is lost in medulloblastoma (Berman et al., 2002). (Aszterbaum et al., 1998), a subset of meningioma, breast carci-
noma, and colon cancer (Xie et al., 1997). Suppression of ShhThese authors concluded that complete loss of Ptc1 expression
was necessary for medulloblastoma formation. However, our signaling could also be beneficial in tumors that do not harbor
mutations in the Shh pathway, but in which Shh signaling isobservation was confirmed by an independent study (Zurawel
et al., 2000), and we have now extended these analyses using important for continuous tumor cell growth (Berman et al., 2003;
Thayer et al., 2003).quantitative real-time PCR, in situ hybridization, Northern blot-
ting (data not shown), and microarray analysis (Lee et al., 2003). The data presented here provide strong support for initiating
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Biosciences). After UV crosslinking, the membrane was hybridized usinghuman clinical trials with molecular inhibitors of the Shh path-
DNA probes for Gli1 (NM_010296.1) nt966–2664, Ptch1 (NM_008957.1)way, such as the Smo suppressor HhAntag. The patient popula-
nt4191–4305 plus the 739 nucleotides of the 3UTR, Ptch2 (NM_008958.1)tions most likely to benefit from such intervention would include
nt652–3549, and Smo (NM_176996.3) nt2824–3962.
Gorlin syndrome patients and patients with sporadic medul-
loblastoma containing mutations in the Shh pathway. One im- Mice
portant challenge in such trials would be to identify a marker that The mice used in this study were generated and maintained on a mixed
C57Bl/6;129Sv background, as described previously (Wetmore et al., 2001).could serve as an indicator for dose-dependent suppression of
Mice were observed daily and euthanized according to NIH-approved institu-Smo signaling. This could be achieved by monitoring changes
tional guidelines when showing signs of increased intracranial pressure orin gene expression, for example, downregulation of Gli1. How-
extracranial tumors were evident. Animals were housed in an Americanever, it may be necessary to utilize surrogate cells affected by
Association of Laboratory Animal Care-accredited facility and maintained in
the treatment, for example, epidermal cells in which the Shh accordance with the NIH Guidelines for the Care and Use of Laboratory
pathway is active, or alternative tumor-specific markers such Animals. The Institutional Animal Care and Use Committee at St. Jude Chil-
dren’s Research Hospital approved all procedures for animal use.as secreted proteins that could be measured in blood or cerebral
spinal fluid, to monitor the efficacy of pathway suppression.
Real-time PCR analysis of gene expressionUltimately, it is likely that success in treating cancer will
6-week-old Ptc1/p53/ mice treated by oral gavage twice daily for 4require the use of several compounds in concert that target
days, with HhAntag at 20 or 100 mg/kg or vehicle. 4 hr following the last
distinct pathways important for tumor cell growth. Our mouse dose, mice were euthanized and their tumor-bearing cerebella were snap
studies with HhAntag offer the hope that such precise, targeted frozen in liquid nitrogen. Total RNA was extracted using the TriPure reagent
molecular interventions could spare children from the devasta- (Roche Diagnostics). 5 ng was analyzed using the real-time RT-PCR ABI
Prism 7900 sequence detection system (Applied Biosystems). Levels ofting effects of surgery, toxic chemotherapy, and exposure to
assayed genes were normalized to 18S rRNA abundance. The sequenceshigh doses of radiation.
of the amplification primers and Taqman probes are: Gli1 primers 5-GCT
TGGATGAAGGACCTTGTG, 5-GCTGATCCAGCCTAAGGTTCTC, probeExperimental procedures
5-CCGGACTCTCCACGCTTCGCC; Sfrp1 primers 5-TCCTCCATGCGACA
ACGA, 5-TGATTTTCATCCTCAGTGCAAACT, probe 5-TGAAGTCAGAGGCell culture, luciferase, and cell growth assays
CCATCATTGAACATCTCTG; Math1 primers 5-ATGCACGGGCTGAACCA,Mouse medulloblastoma cell cultures were established and characterized
5-TCGTTGTTGAAGGACGGGATA, probe 5-CCTTCGACCAGCTGCGCAas previously described (Li et al., 2003). NIH3T3 and medulloblastoma cell
ACG; Ptc1 primers 5-CAAGTGTCGTCCGGTTTGC, 5-CTGTACTCCGAGTcultures were maintained in DMEM (GIBCO-BRL/Invitrogen) under standard
CGGAGGAA, (detecting the wt Ptc1 allele), probe 5-CCTCCTGGTCACACGconditions. Cells were plated at 4 	 104 or 1 	 104 per well in a 24-well
AACAATGGGTC; Ptc2 primers 5-TGGAGCCACCTTGGTACAAGA, 5-GGCplate 24 hr before transfection. 0.25 g of Gli-Firefly luciferase reporter
GCTCAGGAAAGCATGT, probe 5-CTGGCCCTGACAGATGTGGTCCCT;plasmid (Sasaki et al., 1997) and 0.0125 g of Renilla luciferase plasmid
and Reln primers 5-GGCGATGCCCTGGTCTTTAT, 5-TCTGTGACTGAGCA(pRL-SV40) mixed with Fugene 6 were applied to the cells (Roche Diagnos-
GGAGGCA, probe 5-AAAAGGCCAGCACCCGTTACGTGG.tics). Cells were harvested 48 hr after transfection medium containing 0.5%
FBS, ShhN, and HhAntag compound (Curis, Inc., Boston, MA) was applied
Pharmacokineticsto confluent cells. Luciferase assays were performed according to manufac-
Brains were snap frozen 4 hr after the last HhAntag dose, homogenized inturer’s instructions (Dual Luciferase Assay Kit, Promega) and normalized for
PBS, and centrifuged. HhAntag was extracted from the supernatant usingtransfection efficiency using Renilla luciferase activity.
a Strata-X solid phase extraction column (Phenomenex 8B-S100-UBJ). TheCell proliferation was assayed in triplicates using Alamar blue reagent
drug was eluted with methanol/acetonitrile/acetic acid (70/30/0.012), dried,according to the manufacturer’s directions. HhAntag was obtained from
reconstituted with 100l 20% acetonitrile water, and centrifuged, and super-Curis. HhAntag is available from Genentech under a material transfer agree-
natant was transferred into an autosampler vial for injection. Chromato-ment, available at http://www.gene.com/gene/about/collaborations/con-
graphic separation was achieved on a Waters Xterra MSC18 3.5 m, 30 	tracts.jsp. HhAntag details are presented in the US patent WO 2003011219,
2.1 mm column with an isocratic mobile phase of acetonitrile and wateravailable from the web site http://l2.espacenet.com/espacenet/viewer?PN
(50:50). The analytes were detected with a triple quadrupole mass spectrom-WO03011219.
eter, and the ions were monitored in the multiple reaction monitoring (MRM)
mode including m/z 451 (precursor ion) to m/z 150.9 (product ion) for HhAn-Retroviral vectors and retroviral-mediated gene transfer
tag and m/z 328 (precursor ion) to m/z 244 (product ion) for HhAntag-585HA-tagged, full-length mouse Gli1 cDNA was generated by PCR and sub-
(internal standard). The lower limit of quantitation of HhAntag was 5 ng/mlcloned into pCX4pur retroviral-mediated expression vector (GenBank acces-
(signal/noise 
 5), and results from a 5-day validation study demonstratedsion #AB086386). Retroviral-mediated gene transfer was performed as de-
acceptable within-day and between-day precision (CV% values 4.4%scribed previously (Akagi et al., 2003). 72 hr after the infection, cells were
and 5.5%, respectively) and accuracy (range 104.4% to 108.0%).harvested and used for the Northern blotting analyses.
In situ hybridizationCerebellar granule neuron precursor culture and BrdU
Gene expression was evaluated by in situ hybridization as described pre-incorporation assay
viously (Rice et al., 1998). Probes for Gli1, Ptch1, and Ptch2 are describedCerebellar granule neuron precursor cells were isolated from postnatal day
above; Sfrp1 (NM_013834.1) nt239–1200, Math1 (NM_007500.2) nt602–6 C57Bl/6 mice as previously described (Furuya et al., 1998) and plated at
1128, Reln (NM_011261.1) nt5269–5975. Probes were [-33P]UTP radiola-a density of 3 	 105 cells/cm2 onto poly-D-lysine-coated plastic plates (BD
beled. Autoradiography proceeded for 1–10 days. Reference sections wereBioscience), with indicated amounts of ShhN and HhAntag. 10 M BrdU
stained with hematoxylin and eosin. Slides were photographed with a Nikonwas added 2 hr before cells were fixed with 0.5 M HCl, 70% EtOH. BrdU
Coolsnap ES camera mounted onto a Zeiss Stemi 11 Stereo microscope.assays were performed using BrdU labeling and detection kit III (Roche
Diagnositcs) according to manufacturer’s instructions.
Histological analyses
Mice were perfused intracardially with 4% paraformaldehyde and brainsNorthern blot analysis
Total RNA was isolated from snap frozen tissue or cultured cells using were removed and postfixed overnight at 4C. Brains were dehydrated
through a series of ethanols, delipidated in mixed xylenes, and embeddedthe TriPure reagent (Roche Diagnostics), according to the manufacturer’s
instructions. 10 g was separated on 1% agarose gel under denaturing in Paraplast X-TRA (Fisher Scientific). Brains were sectioned at 5 m in the
sagittal plane and mounted on Superfrost slides (Fisher Scientific). Forconditions and transferred onto nylon membrane (Hybond-N, Amersham
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Referenceshistological analyses, sections were stained with haematoxylin and eosin
using standard histological protocols. Slides were photographed using Axio-
plan Zeiss microscope (Zeiss) and RT color SPOT camera (Diagnostic Instru- Akagi, T., Sasai, K., and Hanafusa, H. (2003). Refractory nature of normal
ments). human diploid fibroblasts with respect to oncogene-mediated transforma-
tion. Proc. Natl. Acad. Sci. USA 100, 13567–13572.
Volumetric measurement of tumors Aszterbaum, M., Rothman, A., Johnson, R.L., Fisher, M., Xie, J., Bonifas,
Stained sections taken every 150 m were analyzed using the Bioquant J.M., Zhang, X., Scott, M.P., and Epstein, E.H., Jr. (1998). Identification of
Nova Advanced Image Analysis software. An outline of the remaining normal mutations in the human PATCHED gene in sporadic basal cell carcinomas
IGL and the tumor region was prepared for every section. This analysis was and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110,
inclusive in that any abnormal tissue area was assumed to be tumor. Traces 885–888.
were aligned using the IGL outline as a reference and reconstructed into a
Bai, C.B., Auerbach, W., Lee, J.S., Stephen, D., and Joyner, A.L. (2002).three-dimensional image, and the volume for every tumor was calculated.
Gli2, but not Gli1, is required for initial Shh signaling and ectopic activation
of the Shh pathway. Development 129, 4753–4761.
Immunohistochemistry and detection of apoptosis
Berman, D.M., Karhadkar, S.S., Hallahan, A.R., Pritchard, J.I., Eberhart,Paraffin sections were processed for immunohistochemistry with antibody
C.G., Watkins, D.N., Chen, J.K., Cooper, M.K., Taipale, J., Olson, J.M.,against Ki67 (Novocastra Laboratories) by deparaffinization and rehydration
and Beachy, P.A. (2002). Medulloblastoma growth inhibition by hedgehogfollowed by antigen retrieval in 10 mM sodium citrate at 80C. Slides were
pathway blockade. Science 297, 1559–1561.treated with 1% H2O2, blocked in 10% normal goat serum, and incubated
with primary antibody (1:2000 dilution) overnight at room temperature. Immu- Berman, D.M., Karhadkar, S.S., Maitra, A., Montes De Oca, R., Gerstenblith,
noreactivity was detected using the ABC Elite kit (Vector Laboratories) and M.R., Briggs, K., Parker, A.R., Shimada, Y., Eshleman, J.R., Watkins, D.N.,
diaminobenzidine reagent set (Kirkegaard and Perry Laboratories), according and Beachy, P.A. (2003). Widespread requirement for Hedgehog ligand stim-
ulation in growth of digestive tract tumours. Nature 425, 846–851.to manufacturers’ recommendations. Slides were cover-slipped and ana-
lyzed using an Olympus BX60 microscope. Cells undergoing apoptosis were
Binns, W., James, L.F., Shupe, J.L., and Everett, G. (1963). A congenital
detected using the DeadEnd Colorimetric TUNEL system (Promega), ac- cyclopian-type malformation in lambs induced by maternal ingestion of a
cording to manufacturer’s instructions. Proliferative and apoptotic indexes range plant, Veratrum californicum. Am. J. Vet. Res. 24, 1164–1175.
were determined by counting 900–1300 cells for each tumor.
Chen, J.K., Taipale, J., Cooper, M.K., and Beachy, P.A. (2002). Inhibition of
Hedgehog signaling by direct binding of cyclopamine to Smoothened. GenesSurvival studies
Dev. 16, 2743–2748.A cohort of 25-week-old Ptc1/p53/ mice was treated with HhAntag at
100 mg/kg of body weight, or vehicle alone, by oral gavage, once daily. The Chintagumpala, M., Berg, S., and Blaney, S.M. (2001). Treatment controver-
mice were observed daily and euthanized if any sign of illness could be sies in medulloblastoma. Curr. Opin. Oncol. 13, 154–159.
discerned. The presence of brain tumors was confirmed by gross examina-
Cooper, M.K., Porter, J.A., Young, K.E., and Beachy, P.A. (1998). Teratogen-
tion of dissected brain.
mediated inhibition of target tissue response to Shh signaling. Science 280,
1603–1607.
Statistical considerations for the manuscript
Corcoran, R.B., and Scott, M.P. (2001). A mouse model for medulloblastomaStatXact-5 for Windows was used for all exact statistical analyses (Statistical
and basal cell nevus syndrome. J. Neurooncol. 53, 307–318.Software for Exact Nonparametric Inference, CYTEL Software Corporation).
The assumption that gene expression intensities were from Gaussian distri- Ellison, D. (2002). Classifying the medulloblastoma: insights from morphol-
butions was rejected by the exact Shapiro-Wilk’s test (all p values  0.05); ogy and molecular genetics. Neuropathol. Appl. Neurobiol. 28, 257–282.
thus, the traditional t test is not valid for analyzing these data. Exact Kruskal-
Ellison, D.W., Clifford, S.C., Gajjar, A., and Gilbertson, R.J. (2003). What’sWallis tests were used to compare gene expression intensities, levels of
new in neuro-oncology? Recent advances in medulloblastoma. Eur. J. Paedi-proliferation and apoptosis, as well as tumor volumes between vehicle and
atr. Neurol. 7, 53–66.
treated mice. Cumulative incidence functions of mice euthanized due to
Frank, A.J., Hernan, R., Hollander, A., Lindsey, J.C., Lusher, M.E., Fuller, C.E.,brain tumors in the presence of competing events of euthanasia due to
Clifford, S.C., and Gilbertson, R.J. (2004). The TP53-ARF tumor suppressorother tumors were estimated as discussed by Kalbfleisch and Prentice and
pathway is frequently disrupted in large/cell anaplastic medulloblastoma.compared using exact log-rank tests. All p values are for two-sided tests
Brain Res. Mol. Brain Res. 121, 137–140.and those less than 0.05 were considered statistically significant without
adjustment for multiple testing (Kalbfleisch and Prentice, 1980; Kruskal and Furuya, S., Makino, A., and Hirabayashi, Y. (1998). An improved method for
Wallis, 1952; Shapiro and Wilk, 1965). culturing cerebellar Purkinje cells with differentiated dendrites under a mixed
monolayer setting. Brain Res. Brain Res. Protoc. 3, 192–198.
Acknowledgments
Gabay, L., Lowell, S., Rubin, L.L., and Anderson, D.J. (2003). Deregulation
of dorsoventral patterning by FGF confers trilineage differentiation capacity
We thank the members of the Curran Lab for discussions and comments on CNS stem cells in vitro. Neuron 40, 485–499.
on the manuscript. We thank Youngsoo Lee for help with the real-time PCR
Goodrich, L.V., and Scott, M.P. (1998). Hedgehog and patched in neuralanalyses. We thank James Boyett and Mehmet Kocak for statistical analysis
development and disease. Neuron 21, 1243–1257.of the data. We thank Peter Burger and Charles Eberhart (Johns Hopkins
University) for advice on pathology. S.G. and L.L.R. are employees of Curis, Goodrich, L.V., Milenkovic, L., Higgins, K.M., and Scott, M.P. (1997). Altered
Inc., a publicly traded biotechnology company. This work was supported neural cell fates and medulloblastoma in mouse patched mutants. Science
by CA096832, NS036558, CA-021765, Cancer Center Support (CORE) 277, 1109–1113.
grants from the National Institutes of Health and by the American Lebanese
Gorlin, R.J. (1995). Nevoid basal cell carcinoma syndrome. Dermatol. Clin.and Syrian Associated Charities (ALSAC).
13, 113–125.
Hahn, H., Wicking, C., Zaphiropoulous, P.G., Gailani, M.R., Shanley, S.,
Chidambaram, A., Vorechovsky, I., Holmberg, E., Unden, A.B., Gillies, S.,
et al. (1996). Mutations of the human homolog of Drosophila patched in theReceived: June 29, 2004
nevoid basal cell carcinoma syndrome. Cell 85, 841–851.Revised: August 2, 2004
Accepted: August 19, 2004 Hesselager, G., and Holland, E.C. (2003). Using mice to decipher the molecu-
lar genetics of brain tumors. Neurosurgery 53, 685–695.Published: September 20, 2004
CANCER CELL : SEPTEMBER 2004 239
A R T I C L E
Johnson, R.L., Rothman, A.L., Xie, J., Goodrich, L.V., Bare, J.W., Bonifas, for Gli proteins is essential for HNF-3beta floor plate enhancer activity in
transgenics and can respond to Shh in vitro. Development 124, 1313–1322.J.M., Quinn, A.G., Myers, R.M., Cox, D.R., Epstein, E.H., Jr., and Scott, M.P.
(1996). Human homolog of patched, a candidate gene for the basal cell
Shapiro, S.S., and Wilk, M.B. (1965). An analysis of variance test for normalitynevus syndrome. Science 272, 1668–1671.
(complete samples). Biometrika 52, 591–611.
Kalbfleisch, J.D., and Prentice, R.L. (1980). Statistical Analysis of Failure
Taipale, J., Chen, J.K., Cooper, M.K., Wang, B., Mann, R.K., Milenkovic, L.,
Time Data (New York: Wiley).
Scott, M.P., and Beachy, P.A. (2000). Effects of oncogenic mutations in
Smoothened and Patched can be reversed by cyclopamine. Nature 406,Keeler, R.F., and Binns, W. (1968). Teratogenic compounds of Veratrum
1005–1009.californicum (Durand). V. Comparison of cyclopian effects of steroidal alka-
loids from the plant and structurally related compounds from other sources. Taipale, J., Cooper, M.K., Maiti, T., and Beachy, P.A. (2002). Patched acts
Teratology 1, 5–10. catalytically to suppress the activity of Smoothened. Nature 418, 892–897.
Kimonis, V.E., Goldstein, A.M., Pastakia, B., Yang, M.L., Kase, R., DiGio- Taylor, M.D., Liu, L., Raffel, C., Hui, C.C., Mainprize, T.G., Zhang, X., Agatep,
vanna, J.J., Bale, A.E., and Bale, S.J. (1997). Clinical manifestations in 105 R., Chiappa, S., Gao, L., Lowrance, A., et al. (2002). Mutations in SUFU
persons with nevoid basal cell carcinoma syndrome. Am. J. Med. Genet. predispose to medulloblastoma. Nat. Genet. 31, 306–310.
69, 299–308.
Thayer, S.P., di Magliano, M.P., Heiser, P.W., Nielsen, C.M., Roberts, D.J.,
Kleihues, P., Schauble, B., zur Hausen, A., Esteve, J., and Ohgaki, H. (1997). Lauwers, G.Y., Qi, Y.P., Gysin, S., Fernandez-del Castillo, C., Yajnik, V., et
Tumors associated with p53 germline mutations: a synopsis of 91 families. al. (2003). Hedgehog is an early and late mediator of pancreatic cancer
Am. J. Pathol. 150, 1–13. tumorigenesis. Nature 425, 851–856.
Kruskal, W.H., and Wallis, W.A. (1952). Use of ranks in one-criterion variance Van Dyke, T., and Jacks, T. (2002). Cancer modeling in the modern era:
progress and challenges. Cell 108, 135–144.analysis. J. Am. Stat. Assoc. 47, 583–621.
Wechsler-Reya, R., and Scott, M.P. (2001). The developmental biology ofLee, Y., Miller, H.L., Jensen, P., Hernan, R., Connelly, M., Wetmore, C.,
brain tumors. Annu. Rev. Neurosci. 24, 385–428.Zindy, F., Roussel, M.F., Curran, T., Gilbertson, R.J., and McKinnon, P.J.
(2003). A molecular fingerprint for medulloblastoma. Cancer Res. 63, 5428– Weiner, H.L., Bakst, R., Hurlbert, M.S., Ruggiero, J., Ahn, E., Lee, W.S.,
5437. Stephen, D., Zagzag, D., Joyner, A.L., and Turnbull, D.H. (2002). Induction
of medulloblastomas in mice by sonic hedgehog, independent of Gli1. Can-Li, L., Connelly, M.C., Wetmore, C., Curran, T., and Morgan, J.I. (2003).
cer Res. 62, 6385–6389.Mouse embryos cloned from brain tumors. Cancer Res. 63, 2733–2736.
Wetmore, C., Eberhart, D.E., and Curran, T. (2000). The normal patchedMalkin, D., Li, F.P., Strong, L.C., Fraumeni, J.F., Jr., Nelson, C.E., Kim, D.H.,
allele is expressed in medulloblastomas from mice with heterozygous germ-Kassel, J., Gryka, M.A., Bischoff, F.Z., Tainsky, M.A., et al. (1990). Germ line
line mutation of patched. Cancer Res. 60, 2239–2246.p53 mutations in a familial syndrome of breast cancer, sarcomas, and other
neoplasms. Science 250, 1233–1238. Wetmore, C., Eberhart, D.E., and Curran, T. (2001). Loss of p53 but not ARF
accelerates medulloblastoma in mice heterozygous for patched. Cancer
Park, H.L., Bai, C., Platt, K.A., Matise, M.P., Beeghly, A., Hui, C.C., Naka- Res. 61, 513–516.
shima, M., and Joyner, A.L. (2000). Mouse Gli1 mutants are viable but have
defects in SHH signaling in combination with a Gli2 mutation. Development Williams, J.A., Guicherit, O.M., Zaharian, B.I., Xu, Y., Chai, L., Wichterle, H.,
Kon, C., Gatchalian, C., Porter, J.A., Rubin, L.L., and Wang, F.Y. (2003).127, 1593–1605.
Identification of a small molecule inhibitor of the hedgehog signaling path-
Reifenberger, J., Wolter, M., Weber, R.G., Megahed, M., Ruzicka, T., Lichter, way: effects on basal cell carcinoma-like lesions. Proc. Natl. Acad. Sci. USA
P., and Reifenberger, G. (1998). Missense mutations in SMOH in sporadic 100, 4616–4621.
basal cell carcinomas of the skin and primitive neuroectodermal tumors of
Xie, J., Johnson, R.L., Zhang, X., Bare, J.W., Waldman, F.M., Cogen, P.H.,the central nervous system. Cancer Res. 58, 1798–1803.
Menon, A.G., Warren, R.S., Chen, L.C., Scott, M.P., and Epstein, E.H., Jr.
Rice, D.S., Sheldon, M., D’Arcangelo, G., Nakajima, K., Goldowitz, D., and (1997). Mutations of the PATCHED gene in several types of sporadic extracu-
Curran, T. (1998). Disabled-1 acts downstream of Reelin in a signaling path- taneous tumors. Cancer Res. 57, 2369–2372.
way that controls laminar organization in the mammalian brain. Development
Zurawel, R.H., Allen, C., Wechsler-Reya, R., Scott, M.P., and Raffel, C.125, 3719–3729.
(2000). Evidence that haploinsufficiency of Ptch leads to medulloblastoma
in mice. Genes Chromosomes Cancer 28, 77–81.Sasaki, H., Hui, C., Nakafuku, M., and Kondoh, H. (1997). A binding site
240 CANCER CELL : SEPTEMBER 2004
